STOCK TITAN

Compugen to Present at Upcoming September 2020 Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:

Event: Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Presentation Time: 9:30 AM ET

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 22, 2020
Presentation Time: 9:10 AM ET

A live webcast of each presentation will be accessible in the Investor Relations section of the Compugen website at www.cgen.com. Replays will also be available following each live event.

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. The Company's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124

Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com 
Tel: +1 (646) 597-6989

Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1 (646) 751-4361

Cision View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-september-2020-investor-conferences-301123707.html

SOURCE Compugen Ltd.

Compugen Ltd.

NASDAQ:CGEN

CGEN Rankings

CGEN Latest News

CGEN Stock Data

166.53M
84.69M
5.38%
13.71%
2.34%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Holon

About CGEN

compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib